Marie Gouanvic

Title: Marie Gouanvic: Innovator in Mycobacterial Antigen Vaccines

Introduction

Marie Gouanvic, an accomplished inventor based in Lyons, France, has made significant contributions to the field of immunology through her innovative research and development. With one notable patent to her name, Gouanvic's work focuses on advancing vaccine technologies aimed at combating mycobacterial infections.

Latest Patents

Gouanvic’s patent, titled "Mycobacterial Antigen Vaccine," describes immunogenic combinations that include at least five antigens related to mycobacterial species. This invention encompasses fusion proteins and nucleic acid molecules encoding these combined antigens, providing a comprehensive approach to vaccine development. Additionally, the patent outlines methods for recombinantly producing these antigens and their applications in inducing or stimulating an immune response against infections associated with mycobacteria. It also addresses antibodies directed towards these antigens that can be utilized for diagnostic purposes.

Career Highlights

Throughout her career at Transgene S.A., Marie Gouanvic has proven to be a valuable asset to her team, leveraging her expertise in biotechnology to drive innovation in vaccine development. Her work has had a significant impact in the realm of infectious disease prevention and treatment, particularly in understanding mycobacterial infections.

Collaborations

Gouanvic has collaborated with talented colleagues, including Emmanuel Tupin and Romain Micol, to further her research efforts. Their combined expertise and collaborative spirit have fostered an environment ripe for innovation, leading to the successful development of pioneering vaccine technologies.

Conclusion

Marie Gouanvic stands out as a dedicated inventor in the field of immunology, with her groundbreaking work on mycobacterial antigen vaccines. Her patent reflects her commitment to enhancing public health through scientific innovation and collaboration. As she continues her journey in the biotechnology industry, Gouanvic’s contributions will undoubtedly pave the way for future advancements in vaccine development.